Last updated: February 26, 2026
What Is the Drug and Its Primary Use?
NDC 62135-0826 corresponds to ABACAVIR SULFATE, an antiretroviral medication used predominantly for the treatment of HIV-1 infection. It is commonly prescribed in combination with other antiretrovirals to suppress viral load and improve immune function.
Market Landscape
Global and U.S. Market Size
The HIV antiretroviral market is characterized by mature, high-value segments with consistent demand driven by HIV prevalence, particularly in the United States, sub-Saharan Africa, and Europe.
| Metric |
Value |
Source |
| U.S. HIV drug market size (2022) |
$6.4 billion |
[1] |
| Global HIV drug market (2022) |
$18.7 billion |
[2] |
| Estimated annual growth rate |
4.2% |
[3] |
Key Competitors and Market Share
Current market leaders include Gilead Sciences (JULUCA, Biktarvy), Merck (Pifeltro), and ViiV Healthcare (Tivicay). Abacavir remains a core component, especially in fixed-dose combinations.
| Company |
Leading Products |
Estimated Market Share (2022) |
Notes |
| Gilead |
Biktarvy |
40% |
Dominates in combination therapy |
| ViiV |
Tivicay |
25% |
Key in oral regimens |
| Merck |
Pifeltro |
10% |
Focus on treatment-resistant cases |
Patent Status & Market Entry Barriers
Abacavir was originally developed by GlaxoSmithKline (GSK), with patent protections expiring in the late 2010s. Generic formulations entered the market by 2018, intensifying price competition.
Pricing Dynamics and Projections
Current Pricing Landscape
| Version Type |
Average Wholesale Price (AWP) (per pill) |
Notes |
| Branded (GSK) |
$15 |
GSK's branded formulation |
| Generic (approved post-2018) |
$2-$5 |
Significant price reduction, varying by supplier |
Factors Affecting Prices
- Generic Competition: Entry in 2018 drove prices down by approximately 70%.
- Supply Chain Dynamics: Manufacturing costs, patent litigations, and supply chain disruptions influence pricing.
- Reimbursement Policies: Medicare, Medicaid, and private insurers' formulary decisions impact net prices.
Future Price Trends (2023-2028)
| Year |
Estimated Price Range (per pill) |
Assumptions |
| 2023 |
$2-$4 |
Continued generic supply, stable demand |
| 2025 |
$2-$4 |
No significant patent barriers re-emerge |
| 2028 |
$2-$3 |
Slight decrease expected with market saturation |
Decreases reflect consistent generic competition and increased adoption of fixed-dose combination therapies including abacavir, which may marginally influence individual drug pricing.
Market Opportunities and Risks
Opportunities
- Formulary Inclusion: Widespread inclusion of abacavir-based generics in insurance plans increases volume.
- New Fixed-Dose Combinations: Development of newer, more tolerable fixed-dose regimens can expand market share.
Risks
- Patent Litigations: Potential patent challenges or legal restrictions could impact pricing.
- Pricing Pressure: Rising prominence of cost-effective generics limits revenue potential for branded formulations.
- Regulatory Changes: Policy shifts favoring biosimilars or generics could accelerate price erosion.
Strategic Implications
Investors and pharmaceutical companies should prioritize generic manufacturers and formulation developers. Market entry for biosimilars or innovative delivery mechanisms remains unlikely given the drug's composition.
Key Takeaways
- NDC 62135-0826 (abacavir sulfate) faces a highly commoditized market with aggressive generic competition.
- Pricing per pill has declined significantly since patent expiry, stabilized between $2 and $4.
- The market size remains steady, with a growing shift toward generic and combination therapies.
- Regulatory and legal challenges could influence pricing and market share.
- Future revenue streams will depend on formulary access, patient adherence, and competition from newer treatments.
FAQs
1. What are the primary competitors to abacavir sulfate?
The main competitors include other NRTIs (Nucleoside Reverse Transcriptase Inhibitors) like tenofovir and lamivudine, and combination regimens that integrate these APIs.
2. How does patent expiration affect the drug's market?
Patents expiring in 2018 led to increased generic entry, reducing prices and market exclusivity.
3. What are the prospects for new formulations?
Development of fixed-dose combinations with newer drugs could expand usage but unlikely to significantly affect the price of standalone abacavir sulfate.
4. How do pricing trends compare to other HIV drugs?
Similar drugs, such as tenofovir disoproxil fumarate, experienced comparable price declines post-generic entry, stabilizing around a few dollars per pill.
5. Are biosimilars relevant for this drug?
No. Biosimilars are not relevant since abacavir is a small-molecule drug, not a biologic.
References
[1] IQVIA. (2022). U.S. Prescription Drug Market Reports.
[2] Grand View Research. (2022). HIV Drugs Market Size & Trends.
[3] Statista. (2022). HIV Drugs Market Growth Rate.
